Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted nerve block replace opioids for chemoport surgery?

NCT ID NCT07771712

Symptom relief Sponsor: Indonesia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This trial tests whether a combined nerve block can provide better pain relief than standard local anesthesia for cancer patients undergoing chemoport implantation. The study will compare the two approaches in 80 adults, measuring the need for extra pain medication during the procedure, as well as post-surgery pain and satisfaction. If successful, this technique could reduce opioid use and improve recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Combined pectoserratus plane and superficial cervical plexus block using bupivacaine
What this could lead to
If effective, this nerve block technique could offer cancer patients a more comfortable chemoport implantation with less pain and fewer opioids.
What could go wrong
This is a small, early-stage trial, and the block may not consistently outperform standard care. There are also risks like local anesthetic toxicity or nerve injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Dec 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-65 years. * Diagnosed with cancer requiring elective chemoport implantation for long-term intravenous therapy. * Classified as American Society of Anesthesiologists (ASA) Physical Status II or III. * Scheduled to undergo chemoport implantation under intravenous sedation. * Able to understand the study procedures and provide written informed consent. Exclusion Criteria: * Refusal to participate in the study. * History of burns or infection at the chest wall in the planned injection area. * Presence of a tumor involving the chest wall at the planned injection site. * Known allergy or hypersensitivity to local anesthetic agents. * Obesity, defined as a body mass index (BMI) \>30 kg/m². * Severe coagulation disorders, defined as a platelet count \<50,000/µL or prolonged prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) greater than twice the upper limit of normal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Perioperative analgesia

Contacts and locations

Locations

  • MRCCC Siloam Hospitals Semanggi

    Jakarta, DKI Jakarta, 12930, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.